Stock Analysis

Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?

NasdaqGS:CVRX
Source: Shutterstock

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that CVRx, Inc. (NASDAQ:CVRX) does have debt on its balance sheet. But should shareholders be worried about its use of debt?

Advertisement

When Is Debt A Problem?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we examine debt levels, we first consider both cash and debt levels, together.

What Is CVRx's Debt?

The image below, which you can click on for greater detail, shows that at March 2025 CVRx had debt of US$49.3m, up from US$29.3m in one year. However, it does have US$102.7m in cash offsetting this, leading to net cash of US$53.3m.

debt-equity-history-analysis
NasdaqGS:CVRX Debt to Equity History June 14th 2025

How Healthy Is CVRx's Balance Sheet?

According to the last reported balance sheet, CVRx had liabilities of US$8.51m due within 12 months, and liabilities of US$51.7m due beyond 12 months. Offsetting this, it had US$102.7m in cash and US$9.01m in receivables that were due within 12 months. So it can boast US$51.5m more liquid assets than total liabilities.

This luscious liquidity implies that CVRx's balance sheet is sturdy like a giant sequoia tree. Having regard to this fact, we think its balance sheet is as strong as an ox. Simply put, the fact that CVRx has more cash than debt is arguably a good indication that it can manage its debt safely. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if CVRx can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Check out our latest analysis for CVRx

Over 12 months, CVRx reported revenue of US$53m, which is a gain of 26%, although it did not report any earnings before interest and tax. With any luck the company will be able to grow its way to profitability.

Portfolio Valuation calculation on simply wall st

So How Risky Is CVRx?

We have no doubt that loss making companies are, in general, riskier than profitable ones. And in the last year CVRx had an earnings before interest and tax (EBIT) loss, truth be told. And over the same period it saw negative free cash outflow of US$42m and booked a US$52m accounting loss. But at least it has US$53.3m on the balance sheet to spend on growth, near-term. CVRx's revenue growth shone bright over the last year, so it may well be in a position to turn a profit in due course. By investing before those profits, shareholders take on more risk in the hope of bigger rewards. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should learn about the 3 warning signs we've spotted with CVRx (including 1 which makes us a bit uncomfortable) .

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:CVRX

CVRx

A commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.

Flawless balance sheet low.

Advertisement